Literature DB >> 23618594

Long-term complications in two patients after aortoaortic bypass for midaortic syndrome.

Michael R Go1, Siddharth Bhende, William L Smead, Patrick S Vaccaro.   

Abstract

The midaortic syndrome (MAS) refers to descending thoracic and abdominal aortic coarctation, which is rare and most common in the pediatric population. Open surgical repair, often with aortoaortic bypass, remains a highly effective treatment and is traditionally thought to be definitive despite concerns over patient growth postoperatively. This article presents 2 cases of MAS treated with aortoaortic bypass who developed long-term complications, one related to patient growth and the other to graft-enteric fistula. Consideration must be given to patient growth at operation for MAS, and long-term follow-up is necessary to identify other complications.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23618594     DOI: 10.1016/j.avsg.2012.05.032

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  4 in total

1.  Unlikely culprit: congenital middle aortic syndrome diagnosed in the sixth decade of life.

Authors:  Muhammad Sajawal Ali; Stefan Tchernodrinski; Divyanshu Mohananey; Ahya Sajawal Ali
Journal:  BMJ Case Rep       Date:  2016-08-16

2.  Surgical management of middle aortic syndrome in an adult.

Authors:  Hubert Y Luu; Marisa E Pulcrano; Hong Ton Hua
Journal:  J Vasc Surg Cases Innov Tech       Date:  2020-02-12

3.  Long-segment thoracoabdominal aortic coarctation in a child with Down syndrome.

Authors:  Vladimir Tonello de Vasconcelos; Ruy Guilherme Rodrigues Cal; Adriano Luís Gomes; Simone Aguiar; Maria Fernanda Carvalho de Camargo; José Carlos Costa Baptista-Silva
Journal:  J Vasc Surg Cases       Date:  2015-06-19

Review 4.  Diagnosis and Management of Genetic Causes of Middle Aortic Syndrome in Children: A Comprehensive Literature Review.

Authors:  Cecilia Lazea; Camelia Al-Khzouz; Crina Sufana; Diana Miclea; Carmen Asavoaie; Ioana Filimon; Otilia Fufezan
Journal:  Ther Clin Risk Manag       Date:  2022-03-16       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.